Status:
UNKNOWN
Patient-Derived Xenografts to Reduce Cancer Health Disparities
Lead Sponsor:
University of California, Davis
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Bladder Carcinoma
Gastric Carcinoma
Eligibility:
All Genders
21-100 years
Brief Summary
This trial establishes patient-derived cancer xenografts in addressing cancer health and treatment disparities that disproportionately affect racial/ethnic minorities. Understanding the genetic and re...
Detailed Description
PRIMARY OBJECTIVES: I. Develop and characterize over 200 patient-derived xenografts (PDXs), with at least 50 PDXs each for gastric, liver, bladder, and lung cancers with 60% (approximately) of the PD...
Eligibility Criteria
Inclusion
- Patient receiving treatment for the above 4 cancers (bladder cancer, lung cancer, gastric/stomach cancer, and liver cancer)
- Signed informed consent that will be put on file
Exclusion
- No informed consent obtained
- Specimen unacceptable/degraded/etc.
- Individuals who are not yet adults (infants, children, teenagers)
- Pregnant women
- Prisoners
- Adults unable to consent
Key Trial Info
Start Date :
November 12 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04410302
Start Date
November 12 2019
End Date
December 1 2024
Last Update
October 16 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California, United States, 92868
2
University of California Davis Comprehensive Cancer Center
Sacramento, California, United States, 95817